A four-tier hypothetical roadmap for AI transforming biotech and drug trials
TikorDuro · reddit · 2026-11-17
A Reddit user lays out a tiered hypothetical progression of AI in biotech:
- Tier 0: Processes unchanged but accelerated — statisticians code with Claude, documents drafted by ChatGPT, FDA reviewers adopt Grok; non-trial bottlenecks shrink, but trials still dominate timelines.
- Tier 1: AI in-silico trial simulation reaches 80% accuracy; pharma simply stops pursuing trials the AI predicts will fail, at least doubling the pace of approved therapies.
- Tier 2: 99% prediction accuracy; patient advocates win laws shifting the FDA from trial review to AI-prediction review, with market access resembling today's Phase 4 surveillance; aging becomes a prime intervention target.
- Tier 3: Fully personalized medicine — every visit spins up a simulated trial of drug combinations for a population of one; no disease too rare or mysterious.
The method can be opaque as long as it's correct; candidate discovery isn't the bottleneck since targets already exceed testing capacity.
More from AGI Musings
- MIT's Jacob Andreas trains models to explain their own computations — MacrinePhD · 2026-11-17
- If AI keeps failing at reasoning, why permanently ban systems that could fix it? — TinfoilTricorn · 2026-11-17
- NEJM AI Grand Rounds: physicians may delegate analytical work to AI agents — zakkohane · 2026-11-17
- rauchjulian: traces are the essential new primitive of software development — your intelligence — HamelHusain · 2026-11-17
- UC Berkeley's School of Education recruiting one PhD student in human-centered AI for Fall 2027 — wes_deng · 2026-11-17
- Musk likens relentless RL for superintelligence to Edge of Tomorrow — elonmusk · 2026-11-17